- The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN”
- No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq
NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company has elected to voluntarily delist its common shares from TSX Venture Exchange (“TSXV”), effective at the close of markets on March 16, 2026.
This strategic decision reflects NervGen’s continued maturity and aligns with the Company’s evolution as it enters late-stage development for NVG-291. Following a comprehensive evaluation, the Company determined that maintaining a dual listing on TSXV does not justify the associated costs and administrative requirements. The voluntary delisting is intended to eliminate duplicative exchange fees, reduce legal, accounting, and regulatory complexity, and enable greater management focus on clinical execution and long-term shareholder value creation.
All shareholders, including Canadian shareholders, will continue to maintain full trading access of their common shares on Nasdaq. No action is required by shareholders in connection with the voluntary delisting. Shareholders with account-specific questions are encouraged to contact their respective brokers.
The voluntary delisting from TSXV was approved by the Company’s Board of Directors. In accordance with TSXV policies, shareholder approval is not required as the Company’s common shares are listed on an acceptable alternative market. NervGen will continue to be a reporting issuer under applicable securities laws in all provinces and territories of Canada.
In connection with the voluntary delisting from TSXV, the Company has terminated its previously announced at-the-market equity program (the “ATM Program”), launched on December 19, 2025. From January 1, 2026, through March 12, 2026, the Company issued 245 common shares under the ATM Program at a weighted average price of $6.20 per common share, for aggregate net proceeds of $1,489.
